TN2011000268A1 - Combinaison antitumorale associant l'ave 8062 et le docetaxel - Google Patents

Combinaison antitumorale associant l'ave 8062 et le docetaxel

Info

Publication number
TN2011000268A1
TN2011000268A1 TN2011000268A TN2011000268A TN2011000268A1 TN 2011000268 A1 TN2011000268 A1 TN 2011000268A1 TN 2011000268 A TN2011000268 A TN 2011000268A TN 2011000268 A TN2011000268 A TN 2011000268A TN 2011000268 A1 TN2011000268 A1 TN 2011000268A1
Authority
TN
Tunisia
Prior art keywords
docetaxel
ave
antitumor combination
combination associating
antitumor
Prior art date
Application number
TN2011000268A
Other languages
English (en)
Inventor
Michele Besenval
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000268(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TN2011000268A1 publication Critical patent/TN2011000268A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L' invention est relative à une combinaison antitumorale et séquentielle d'AVE8062 ou d'un sel d'AVE8062 et de docetaxel caractérisée en ce que 1AVE8062 est administré à un patient à une dose comprise entre 10 et 50 mg/m2 puis un jour different de la semaine, de preference apres un intervalle de 24 heures, le docetaxel à une dose comprise entre 50 et 120 mg/m2.
TN2011000268A 2008-12-12 2011-05-24 Combinaison antitumorale associant l'ave 8062 et le docetaxel TN2011000268A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0806979A FR2939665B1 (fr) 2008-12-12 2008-12-12 Combinaison antitumorale associant l'ave8062a et le docetaxel
PCT/FR2009/052475 WO2010067027A1 (fr) 2008-12-12 2009-12-10 Combinaison antitumorale associant l'ave8062 et le docetaxel

Publications (1)

Publication Number Publication Date
TN2011000268A1 true TN2011000268A1 (fr) 2012-12-17

Family

ID=40790630

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000268A TN2011000268A1 (fr) 2008-12-12 2011-05-24 Combinaison antitumorale associant l'ave 8062 et le docetaxel

Country Status (27)

Country Link
US (1) US20120004294A1 (fr)
EP (1) EP2376076A1 (fr)
JP (1) JP2012511554A (fr)
KR (1) KR20110104932A (fr)
CN (1) CN102245175A (fr)
AR (1) AR074599A1 (fr)
AU (1) AU2009326220A1 (fr)
BR (1) BRPI0923349A2 (fr)
CA (1) CA2746475A1 (fr)
CL (1) CL2011001316A1 (fr)
CO (1) CO6390037A2 (fr)
CR (1) CR20110319A (fr)
EA (1) EA201170803A1 (fr)
EC (1) ECSP11011112A (fr)
FR (1) FR2939665B1 (fr)
IL (1) IL213458A0 (fr)
MA (1) MA32955B1 (fr)
MX (1) MX2011006253A (fr)
NI (1) NI201100114A (fr)
PA (1) PA8853301A1 (fr)
PE (1) PE20120125A1 (fr)
SG (1) SG172071A1 (fr)
TN (1) TN2011000268A1 (fr)
TW (1) TW201032798A (fr)
UY (1) UY32318A (fr)
WO (1) WO2010067027A1 (fr)
ZA (1) ZA201104358B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
EP1351573A4 (fr) 2000-12-22 2007-03-28 Bristol Myers Squibb Co Procedes relatifs a la modulation de la croissance tumorale et de la metastase
US20050209310A1 (en) 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines

Also Published As

Publication number Publication date
CN102245175A (zh) 2011-11-16
JP2012511554A (ja) 2012-05-24
ZA201104358B (en) 2012-09-26
EA201170803A1 (ru) 2011-12-30
MX2011006253A (es) 2011-11-04
AR074599A1 (es) 2011-01-26
EP2376076A1 (fr) 2011-10-19
PE20120125A1 (es) 2012-02-23
AU2009326220A1 (en) 2011-07-07
CA2746475A1 (fr) 2010-06-17
WO2010067027A1 (fr) 2010-06-17
CR20110319A (es) 2011-09-20
ECSP11011112A (es) 2011-07-29
KR20110104932A (ko) 2011-09-23
FR2939665A1 (fr) 2010-06-18
TW201032798A (en) 2010-09-16
FR2939665B1 (fr) 2011-10-07
US20120004294A1 (en) 2012-01-05
UY32318A (es) 2010-07-30
NI201100114A (es) 2011-12-13
IL213458A0 (en) 2011-07-31
PA8853301A1 (es) 2010-07-27
BRPI0923349A2 (pt) 2015-07-21
MA32955B1 (fr) 2012-01-02
CL2011001316A1 (es) 2011-10-28
CO6390037A2 (es) 2012-02-29
SG172071A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ECSP13012423A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CY1116931T1 (el) Στοματικο σκευασμα μεταδοξινης
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
CY1119560T1 (el) Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας
CY1117831T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
EA201171366A1 (ru) Противоопухолевая комбинация, содержащая ave8062 и сорафениб
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
RU2014148918A (ru) Композиции и способы повышения выносливости и мышечной массы
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
TN2011000268A1 (fr) Combinaison antitumorale associant l'ave 8062 et le docetaxel
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
TR200904341A2 (tr) Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
ATE508750T1 (de) Derivate von vitamin d und ihre verwendung in der therapie
AR053855A1 (es) Metodo para la administracion de capecitabina